Abstract |
The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.
|
Authors | T D Rozen, M L Oshinsky, C A Gebeline, K C Bradley, W B Young, A L Shechter, S D Silberstein |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 22
Issue 2
Pg. 137-41
(Mar 2002)
ISSN: 0333-1024 [Print] England |
PMID | 11972582
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Coenzymes
- Ubiquinone
- coenzyme Q10
|
Topics |
- Adult
- Coenzymes
- Female
- Humans
- Incidence
- Male
- Medical Records
- Migraine Disorders
(drug therapy, epidemiology)
- Time Factors
- Ubiquinone
(analogs & derivatives, therapeutic use)
|